Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.

Damiano BaronciniAngelo GhezziClara GuaschinoLucia MoiolaMassimo FilippiAntonio IannielloCarlo PozzilliRoberta LanzilloVincenzo Brescia-MorraMonica MargoniPaolo GalloGraziella CallariLuigi GrimaldiGiacomo LusMassimiliano CalabreseMarta SimoneGirolama Alessandra MarfiaSarah RasiaDaniela CargneluttiGiancarlo ComiMauro Zaffaroninull null

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022)

NAT treatment maintains its high efficacy for a long time in pediatric MS patients, with no new safety issues.

Keyphrases

multiple sclerosis
mass spectrometry
ms ms
cross sectional
clinical trial
double blind
childhood cancer